Dongwha Pharm.Co.,Ltd

000020.KS

000020.KSDongwha Pharm.Co.,Ltd KR flag

KSE

7,730.00

KRW

+20.00

(+0.26%)

214.26BMarket Cap

Nov 13Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7000020008

Return %

Stock

S&P500

-23.24

32.83

-58.77

33.33

-1.53

95.62

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	8,397.84	8,006.53	7,835.73	7,653.03	8,038.77	8,583.72	9,362.01	11,114.85	11,118.89	9,858.88	10,608.75	12,292.01	13,042.31	14,662.43
Basic EPS, GAAP	632.96	47	36	177	202	949	1,700	365	330	1,033	647	736	991	502.39
Free Cash Flow per Basic Share	1,305.38	658.88	71.4	424.11	670.15	830.61	-719.3	-292.24	281.61	801.3	407.56	329.64	101.89	104
Dividend per Share	100	100.12	79.5	70.09	80.48	80	110.05	150.12	119.93	120.05	179.92	179.9	179.95	180.3
Book Value per Share	7,184.92	7,082.5	7,047.26	7,207.16	7,279.76	8,137.55	9,685.58	8,103.22	8,167.12	10,804.67	11,522.66	12,273.14	12,922.78	- -
Tangible Book Value per Share	8,034.06	7,986.02	7,790.38	7,980.92	8,056.22	8,909.48	10,516.56	10,578.94	10,651.68	11,802.35	12,381.97	13,106.04	12,661.99	14,782.18
Basic Weighted Avg Shares	28	28	28	28	28	28	28	28	28	28	28	28	28	28
Sales/Revenue/Turnover	234,562	223,372	220,241	213,472	223,201	237,471	258,882	306,603	307,150	272,075	293,018	340,426	361,109	405,746
Operating Margin (%)	10.92	4.48	0.94	2.5	2.16	4.74	4.24	3.66	3.11	8.51	7.68	8.79	5.2	15.19
Depreciation Expense	12,457	12,201	12,532	12,637	11,864	11,744	11,501	11,357	11,485	10,707	12,093	12,509	13,896	11,273
Net Income, GAAP	17,679	1,311	1,012	4,937	5,609	26,254	47,009	10,069	9,116	28,508	17,870	20,383	27,438	13,902
Effective Tax Rate (%)	7.11	84.44	- -	8.6	6.53	26.37	27.92	30.75	43.92	14.64	26.18	6.47	23.59	29.45
Profit Margin (%)	7.54	0.59	0.46	2.31	2.51	11.06	18.16	3.28	2.97	10.48	6.1	5.99	7.6	3.43
Working Capital	44,461	38,636	43,387	51,633	66,033	96,040	173,783	167,089	179,742	155,249	153,737	151,965	131,566	130,066
LT Debt	10,000	- -	2,000	- -	- -	- -	- -	- -	5,116	4,075	5,056	2,044	27,884	- -
Total Equity	229,624	226,995	227,231	229,726	230,118	252,925	296,945	297,401	299,708	342,682	360,133	378,673	407,056	409,060
Return on Invested Capital (%)	9.16	0.61	- -	2.06	1.91	3.36	2.77	2.53	1.74	5.82	4.48	7.3	3.4	10.67
Return on Capital (%)	9.21	0.68	- -	2.52	2.8	12.24	19.07	4.1	4.05	10.24	4.92	5.55	6.71	7.06
Return on Common Equity (%)	10.16	0.66	0.51	2.47	2.78	12.29	19.07	4.1	4.06	10.89	5.8	6.19	7.87	7.83

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	5.4%	3.74%	6.08%
Net Income, GAAP	98.47%	42.92%	34.61%
Free Cash Flow	17.49%	-29.86%	-69.1%
Total Cash Common Dividend	- -	- -	- -
Total Equity	6.16%	6.57%	7.5%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Doh Joon Yoon
Full Time Employees: 792
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: FastFive Tower Seoul South Korea 04522
IPO Date: Jan 4, 2000
Website: dong-wha.co.kr
Similar Companies: Priority Aviation, Inc. (PJET)
Hybio Pharmaceutical Co., Ltd. (300199.SZ)
MERCK Kommanditgesellschaft auf Aktien (MER.SW)
Ipsen S.A. (IPN.PA)
Willow Biosciences Inc. (WLLW.TO)
Suven Life Sciences Limited (SUVEN.NS)
Business: Dongwha Pharm Co., Ltd. manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxant/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and teeth, hepatic protector, nutrient, tonic, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics. The company was founded in 1897 and is based in Seoul, South Korea.

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	8,397.84	8,006.53	7,835.73	7,653.03	8,038.77	8,583.72	9,362.01	11,114.85	11,118.89	9,858.88	10,608.75	12,292.01	13,042.31	14,662.43
Basic EPS, GAAP	632.96	47	36	177	202	949	1,700	365	330	1,033	647	736	991	502.39
Free Cash Flow per Basic Share	1,305.38	658.88	71.4	424.11	670.15	830.61	-719.3	-292.24	281.61	801.3	407.56	329.64	101.89	104
Dividend per Share	100	100.12	79.5	70.09	80.48	80	110.05	150.12	119.93	120.05	179.92	179.9	179.95	180.3
Book Value per Share	7,184.92	7,082.5	7,047.26	7,207.16	7,279.76	8,137.55	9,685.58	8,103.22	8,167.12	10,804.67	11,522.66	12,273.14	12,922.78	- -
Tangible Book Value per Share	8,034.06	7,986.02	7,790.38	7,980.92	8,056.22	8,909.48	10,516.56	10,578.94	10,651.68	11,802.35	12,381.97	13,106.04	12,661.99	14,782.18
Basic Weighted Avg Shares	28	28	28	28	28	28	28	28	28	28	28	28	28	28
Sales/Revenue/Turnover	234,562	223,372	220,241	213,472	223,201	237,471	258,882	306,603	307,150	272,075	293,018	340,426	361,109	405,746
Operating Margin (%)	10.92	4.48	0.94	2.5	2.16	4.74	4.24	3.66	3.11	8.51	7.68	8.79	5.2	15.19
Depreciation Expense	12,457	12,201	12,532	12,637	11,864	11,744	11,501	11,357	11,485	10,707	12,093	12,509	13,896	11,273
Net Income, GAAP	17,679	1,311	1,012	4,937	5,609	26,254	47,009	10,069	9,116	28,508	17,870	20,383	27,438	13,902
Effective Tax Rate (%)	7.11	84.44	- -	8.6	6.53	26.37	27.92	30.75	43.92	14.64	26.18	6.47	23.59	29.45
Profit Margin (%)	7.54	0.59	0.46	2.31	2.51	11.06	18.16	3.28	2.97	10.48	6.1	5.99	7.6	3.43
Working Capital	44,461	38,636	43,387	51,633	66,033	96,040	173,783	167,089	179,742	155,249	153,737	151,965	131,566	130,066
LT Debt	10,000	- -	2,000	- -	- -	- -	- -	- -	5,116	4,075	5,056	2,044	27,884	- -
Total Equity	229,624	226,995	227,231	229,726	230,118	252,925	296,945	297,401	299,708	342,682	360,133	378,673	407,056	409,060
Return on Invested Capital (%)	9.16	0.61	- -	2.06	1.91	3.36	2.77	2.53	1.74	5.82	4.48	7.3	3.4	10.67
Return on Capital (%)	9.21	0.68	- -	2.52	2.8	12.24	19.07	4.1	4.05	10.24	4.92	5.55	6.71	7.06
Return on Common Equity (%)	10.16	0.66	0.51	2.47	2.78	12.29	19.07	4.1	4.06	10.89	5.8	6.19	7.87	7.83

	Dec'23	Mar'24	Jun'24
ST Debt	19,217	5,628	- -
LT Borrowings	16,128	16,000	- -
LT Finance Leases	11,756	11,040	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	28	28	28
Market Capitalization	284,261	260,142	223,040

	Dec'23	Mar'24	Jun'24
Total Current Assets	237,700	233,656	226,560
Accounts Receivable, Net	64,716	69,956	- -
Cash, Cash Equivalents & STI	88,830	76,466	- -
Inventories	70,697	70,392	- -
Total Current Liabilities	106,134	100,387	96,494
Payables & Accruals	- -	- -	- -
ST Debt	19,217	5,628	- -
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	189	217	215	- -	736
2023	453	271.26	213.96	- -	991
2024	108	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	85,294	87,218	83,456	84,459	340,426
2023	99,420	89,990	87,457	84,241	361,109
2024	118,886	115,162	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	179.81	- -	- -	- -	179.9
2023	180.01	- -	- -	- -	179.95
2024	180.34	- -	- -	- -	- -

Dongwha Pharm.Co.,Ltd

Growth Rates

(avg. rate of change)

Company Description

Capital Structure

Working Capital

Growth Rates

(avg. rate of change)

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year